Towards Healthcare
Bacteriophage Market Size Expands USD 124.09 Million by 2034

Bacteriophage Market Opportunities and Top Key Players

Based on market forecasts, the bacteriophage sector will expand from USD 55.35 million in 2024 to USD 124.09 million by 2034, experiencing a CAGR of 8.44%. The increasing incidence of antimicrobial resistance and the rising prevalence of infectious diseases bolster market growth. The availability of state-of-the-art research and development facilities and the growing demand for personalized medicines contribute to North America’s dominance.

Content

  • Last Updated: 01 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

With a bacteriophage market size of USD 124.09 million by 2034 and a CAGR of 8.44%

AI is revolutionizing the bacteriophage space by enhancing phage-host interaction prediction, automating genome editing, and accelerating drug discovery.

While North America dominates due to advanced infrastructure and government support, Asia-Pacific is the fastest-growing region, driven by rising infectious disease prevalence, increasing healthcare spending, and strong public health initiatives

The phage probiotics segment is expected to grow at the highest CAGR, driven by increasing demand for gut health solutions.

Major challenges include host-specificity limitations and phage resistance development.

Strategic collaborations, such as the PHAXIAM-Technophage and NexaBiome-JAFRAL partnerships, are critical for scaling manufacturing, GMP compliance, and clinical trial acceleration

The regulatory environment is still evolving and fragmented. While the FDA and EMA are evaluating frameworks for phage therapies, regulatory clarity is lacking in many regions.
Any Questions